| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | 0.17 | 2e-06 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | 0.24 | 4e-06 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.15 | 7e-06 |
| mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | 0.14 | 3e-05 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | -0.19 | 0.0002 |
| mRNA | tivozanib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0004 |
| mRNA | SB 505124 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0006 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | BMS-270394 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.16 | 0.002 |